MatthewStevenDietzDOMSEd

Clinical Trials

• Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) Start of enrollment: 2020 Dec 31

  Active, not recruiting

  Phase 2

• A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Start of enrollment: 2020 Oct 19

  Recruiting

  Phase 2

• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2021 May 03

  Active, not recruiting

  Phase 2

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2020 Oct 13

  Active, not recruiting

  Phase 2

• A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery Start of enrollment: 2020 Oct 07

  Active, not recruiting

  Phase 2

• A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue Start of enrollment: 2022 Nov 14

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all